MedTrace Logo

Study to Explore Post Surgical Outcomes Using Point-of-Gaze, Electromyography and Elastography of the SCM

NCT05059340 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-04-18

No results posted yet for this study

Summary

The side effects following post surgical neck dissection treatment for tumours in the head and neck (HN) region are weakness of the shoulder and neck muscles, numbness and reduced sensation around the neck and shoulder region and a general impact on the participant's overall fitness. While survival has been emphasized as an important outcome, recovery of treatment-related morbidity and return to pre-treatment quality of life (QOL) for participants after cancer treatment is equally important.

Sternocleidomastoid (SCM) muscle functions to turn the head to the left or right. In particular while performing neck dissections, SCM dissection is a common step. The side effects of SCM dissection is a stiff neck or reduced neck movements. To objectively measure the outcome of the SCM muscle function, it is necessary to determine what is the normal range of motion in healthy subjects turning to the left and right to look at objects in a specific location or Point-of gaze (POG) procedure, as well as the Electromyography (EMG) of the SCM during the movement.

In this normative study, 20 healthy subjects will be recruited to perform this POG assessment as well as EMG and Elastography (ETG) testing of the SCM on the left and right side. Outcome measures will include

1. neck range of motion for flexion, side flexion and rotation
2. EMG activation patterns for SCM

2\) muscle thickness \& stiffness (as determined by grey scale ultrasound (US) and ETG, respectively) of the SCM

The investigators hypothesize that there will not be any significant differences of POG, EMG and ETG measurements between the left and right side of the SCM in healthy subjects.

Conditions

Sponsors & Collaborators

  • National Cancer Centre, Singapore

    collaborator OTHER

  • Singapore General Hospital

    lead OTHER

Principal Investigators

  • Celia Ia Choo Tan, PhD · SingHealth Services

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-02
Primary Completion
2021-11-30
Completion
2022-10-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05059340 on ClinicalTrials.gov